JAMES SAPIRSTEIN Insider Trading $HEPA Hepion Pharmaceuticals, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JAMES SAPIRSTEIN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JAMES SAPIRSTEIN. JAMES SAPIRSTEIN is Director in RespireRx Pharmaceuticals Inc. ($RSPI) and Chief Executive Officer in Alliqua BioMedical, Inc. ($ALQA) and Interim CEO in MARIZYME INC ($MARZ) and Director in Enochian Biosciences Inc ($DDRT) and Director in Probility Media Corp ($PBYA) and Chief Executive Officer in ContraVir Pharmaceuticals, Inc. ($CTRV) and PRESIDENT AND CEO in AzurRx BioPharma, Inc. ($AZRX).
JAMES SAPIRSTEIN in Hepion Pharmaceuticals, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JAMES SAPIRSTEIN: Chief Executive Officer
Holdings: 492,819 shares
Current Value: $689,947
Latest Transaction: Jan 05 2018
$HEPA Market Capitalization: $85.72M
$HEPA Previous Close: $1.40
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JAMES SAPIRSTEIN in Hepion Pharmaceuticals, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALQA, AZRX, ENOB, HEPA, MARZ, PBYA, RSPI
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 05 2018 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Grant | A | 0.00 | 322,092 | 0 | 492,819 | 170.7 K to 492.8 K (+188.66 %) |
| Jul 07 2017 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Grant | A | 0.00 | 141,061 | 0 | 170,727 | 29.7 K to 170.7 K (+475.50 %) |
| Mar 07 2017 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Option Exercise | A | 1.48 | 313,898 | 464,569 | 2,761,129 | |
| Mar 07 2017 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Option Exercise | A | 1.43 | 313,898 | 448,874 | 2,447,231 | |
| Oct 31 2016 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Option Exercise | M | 1.50 | 16,666 | 24,999 | 2,133,334 | |
| Oct 31 2016 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Buy | M | 1.50 | 16,666 | 24,999 | 29,666 | 13 K to 29.7 K (+128.20 %) |
| Jun 14 2016 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Option Exercise | A | 0.99 | 500,000 | 495,000 | 2,150,000 | |
| Feb 18 2016 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Buy | P | 1.00 | 10,000 | 10,000 | 13,000 | 3 K to 13 K (+333.33 %) |
| Dec 01 2015 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Buy | P | 2.15 | 500 | 1,075 | 3,000 | 2.5 K to 3 K (+20.00 %) |
| Nov 24 2015 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Buy | P | 1.64 | 2,500 | 4,100 | 2,500 | 0 to 2.5 K |
| Jun 08 2015 | CTRV | ContraVir Pharmace ... | SAPIRSTEIN JAMES | Chief Executive Off ... | Option Exercise | A | 3.60 | 150,000 | 540,000 | 1,650,000 |
Page: 1